Optimizing Oncology and Rare Disease Clinical Trials through Science, Patient Engagement, and Investigator Alignment
Oncology and rare disease trials present distinct challenges, from complex treatment protocols to geographic and logistical barriers for patients with limited mobility.
In the latest Pharma’s Almanac article, Dave Selkirk, President of Ergomed Clinical Research, shares Ergomed’s unique approach to supporting oncology and rare disease trials. This strategy leverages Ergomed’s scientific expertise, global footprint, and patient-focused, hybrid trial models to reduce barriers for patients and investigators alike.
Key learnings:
- Implementing hybrid trial models to reduce patient travel
- Leveraging dedicated engagement teams for patient and investigator support
- Utilizing global expertise for regulatory and cultural insights
- Enhancing data-driven trial intelligence
Read the “Optimizing Oncology and Rare Disease Clinical Trials by Focusing on Science and Aligning with Patients and Investigators” article to learn how Ergomed’s approach transforms patient engagement and supports trial success.
"*" indicates required fields